Bench-to-bedside review: Endothelial cell dysfunction in severe sepsis: a role in organ dysfunction?

被引:94
作者
Vallet, B [1 ]
机构
[1] Univ Hosp, Dept Anesthesiol & Intens Care, Lille, France
[2] Univ Hosp, Dept Pharmacol, Lille, France
来源
CRITICAL CARE | 2003年 / 7卷 / 02期
关键词
coagulation; endothelial cell; monocyte; sepsis; shock; tissue factor; tissue oxygenation; tissue perfusion; vascular reactivity;
D O I
10.1186/cc1864
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
During the past decade a unifying hypothesis has been developed to explain the vascular changes that occur in septic shock on the basis of the effect of inflammatory mediators on the vascular endothelium. The vascular endothelium plays a central role in the control of microvascular flow, and it has been proposed that widespread vascular endothelial activation, dysfunction and eventually injury occurs in septic shock, ultimately resulting in multiorgan failure. This has been characterized in various models of experimental septic shock. Now, direct and indirect evidence for endothelial cell alteration in humans during septic shock is emerging. The present review details recently published literature on this rapidly evolving topic.
引用
收藏
页码:130 / 138
页数:9
相关论文
共 88 条
[1]   Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J].
Annane, D ;
Sébille, V ;
Charpentier, C ;
Bollaert, PE ;
François, B ;
Korach, JM ;
Capellier, G ;
Cohen, Y ;
Azoulay, E ;
Troché, G ;
Chaumet-Riffaut, P ;
Bellissant, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07) :862-871
[2]   MICROVASCULAR FUNCTION AND RHEOLOGICAL CHANGES IN HYPERDYNAMIC SEPSIS [J].
ASTIZ, ME ;
DEGENT, GE ;
LIN, RY ;
RACKOW, EC .
CRITICAL CARE MEDICINE, 1995, 23 (02) :265-271
[3]   Plasma levels of the three endothelial-specific proteins von Willebrand factor, tissue factor pathway inhibitor, and thrombomodulin do not predict the development of acute respiratory distress syndrome [J].
Bajaj, MS ;
Tricomi, SM .
INTENSIVE CARE MEDICINE, 1999, 25 (11) :1259-1266
[4]   Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study [J].
Baudo, F ;
Caimi, TM ;
de Cataldo, F ;
Ravizza, A ;
Arlati, S ;
Casella, G ;
Carugo, D ;
Palareti, G ;
Legnani, C ;
Ridolfi, L ;
Rossi, R ;
D'Angelo, A ;
Crippa, L ;
Giudici, D ;
Gallioli, G ;
Wolfler, A ;
Calori, G .
INTENSIVE CARE MEDICINE, 1998, 24 (04) :336-342
[5]  
Bauer Philippe R., 2002, Pathophysiology, V8, P141, DOI 10.1016/S0928-4680(02)00007-X
[6]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[7]  
Bhagat K, 1996, CARDIOVASC RES, V32, P822
[8]   Local venous responses tea endotoxin in humans [J].
Bhagat, K ;
Collier, J ;
Vallance, P .
CIRCULATION, 1996, 94 (03) :490-497
[9]  
BLANN AD, 1992, CLIN EXP IMMUNOL, V90, P88
[10]  
Bombeli T, 1997, THROMB HAEMOSTASIS, V77, P408